Akums Drugs Q2 FY27 Results: Reporting Date Remains Unclear

Akums Drugs and Pharmaceuticals Limited has not established a single confirmed Q2 FY27 results date in the provided disclosures, while its latest reported Q1 FY27 revenue was ₹1,166.63 crore and net profit was ₹100.98 crore. The September 2026 quarter is important because it follows a quarter of improved profitability and will be compared with Q2 FY26 revenue of ₹1,049.90 crore and profit of ₹42.70 crore.

When will Akums Drugs report Q2 FY27 results?

The available information gives conflicting dates for Akums Drugs' Q2 FY27 results, so investors should treat the reporting schedule as unconfirmed until an exchange filing is available. One earnings calendar lists 2 November 2026 as the upcoming Q2 FY26-27 earnings date, while another calendar lists a board meeting and Q2 2027 earnings release on 4 November 2026.

A separate results preview stated that Akums Drugs had not filed a board-meeting intimation with the NSE or BSE as of 8 September 2026. It also noted that Indian listing rules require September-quarter results to be published within 45 days of the quarter-end, which placed the outer deadline at 14 November 2026. The Q2 FY27 reporting period covers 1 July 2026 to 30 September 2026.

The company has also announced a virtual investor and analyst conference call for 3 November 2026 at 12:00 PM IST to discuss unaudited Q2 FY27 results. Managing Director Sanjeev Jain and CFO Sumeet Sood are named as participants. The supplied notice says the call will provide insight into the quarter but will not contain forward guidance or financial updates.

What did Akums Drugs report in Q1 FY27?

Akums Drugs reported Q1 FY27 revenue of ₹1,166.63 crore, gross profit of ₹133 crore and net profit of ₹100.98 crore. Revenue increased 0.76% quarter on quarter from ₹1,157.87 crore, while gross profit rose 19.72% and net profit rose 24.13% from the preceding quarter.

On a year-on-year basis, the reported Q1 FY27 revenue increase was 13.92%, gross profit growth was 45.15%, and net profit growth was 56.11%. These figures show that profit growth outpaced revenue growth in the June 2026 quarter. However, the supplied material does not provide a detailed management explanation for the change in gross profit or net profit.

The quarterly data also show revenue of ₹1,197.01 crore and profit of ₹100.98 crore for the most recent quarter in one results preview. Because the supplied sources contain differing revenue references for the latest quarter, investors should rely on the company’s filed financial statements and exchange disclosures for the final reported line items.

What is the comparison base for the September 2026 quarter?

Akums Drugs will be measured against Q2 FY26 revenue of ₹1,049.90 crore and profit of ₹42.70 crore, according to the supplied quarterly-results preview. These figures relate to the September 2025 quarter and provide the stated year-on-year comparison base for the Q2 FY27 release.

The comparison is relevant because the latest reported Q1 FY27 net profit of ₹100.98 crore was substantially above that Q2 FY26 profit base. But Q1 and Q2 are separate reporting periods, and the supplied information provides no estimate for Q2 FY27 revenue or profit. It would therefore be inappropriate to infer the September-quarter outcome from the June-quarter performance alone.

Some supplied calendar data present quarterly sales in million rupees, including ₹11,666 million for FY2027 Q1, equivalent to ₹1,166.60 crore. This is broadly consistent with the reported Q1 FY27 revenue of ₹1,166.63 crore after unit conversion and rounding. All absolute financial values in this report are presented in crore rupees for consistency.

Why does the Q2 FY27 filing matter for investors?

The Q2 FY27 filing matters because it will provide the next reported measure of Akums Drugs' revenue, profitability and operating performance after Q1 FY27. The Q1 data showed modest sequential revenue growth but faster growth in gross profit and net profit, making the sustainability of profitability a key point for investors to assess from the filed results.

The release will also clarify whether the company’s September-quarter revenue and profit have advanced against the Q2 FY26 base. Until unaudited results are published through the appropriate regulatory channel, no verified Q2 FY27 financial outcome is available in the supplied information. The stated investor call may offer management commentary once the results are released.

For shareholders, the uncertainty over the precise reporting date is itself relevant. Result dates can affect when investors receive audited or unaudited financial information, but the supplied materials do not indicate a delay beyond the regulatory deadline. The documented 14 November 2026 outer deadline remains the clearest compliance reference included in the source material.

Conclusion

Akums Drugs enters the Q2 FY27 reporting period after posting Q1 FY27 revenue of ₹1,166.63 crore and net profit of ₹100.98 crore, with both gross profit and net profit growing faster than revenue year on year. The immediate issue is the lack of one consistent results date across the supplied calendars, rather than any confirmed Q2 financial result.

Investors should watch for the company’s exchange filing of September 2026-quarter results, the scheduled 3 November 2026 investor and analyst call, and clarification of whether the release occurs on 2 or 4 November 2026. If neither date produces a filing, the supplied regulatory timeline identifies 14 November 2026 as the outer deadline for publication.